Imipraminoxide
Chemical compound
From Wikipedia, the free encyclopedia
Imipraminoxide (brand names Imiprex, Elepsin), or imipramine N-oxide, is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1960s for the treatment of depression.[3][4][5][6]
| |
 | |
| Clinical data | |
|---|---|
| Trade names | Imiprex, Elepsin |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | Intravenous: 1.8 hours[2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.027.188 |
| Chemical and physical data | |
| Formula | C19H24N2O |
| Molar mass | 296.414 g·mol−1 |
Imipraminoxide is both an analogue and a metabolite of imipramine, and has similar effects.[7][8][9][10] However, in clinical trials, imipraminoxide was found to have a faster onset of action, slightly higher efficacy, and fewer and less marked side effects, including diminished orthostatic hypotension and anticholinergic effects like dry mouth, sweating, dizziness, and fatigue.[7][8][9][10][11][12]
Imipraminoxide's pharmacology has not been well elucidated, but based on its very close relationship with imipramine, it likely acts as a serotonin and norepinephrine reuptake inhibitor and serotonin, adrenenaline, histamine, and muscarinic acetylcholine receptor antagonist, though with weaker antiadrenergic and anticholinergic actions.[11][12]
Imipraminoxide has been said to be a prodrug of imipramine.[13]
